Stonebrook Private Inc. Raises Holdings in DexCom, Inc. (NASDAQ:DXCM)

Stonebrook Private Inc. increased its holdings in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) by 96.3% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 8,370 shares of the medical device company's stock after purchasing an additional 4,106 shares during the quarter. Stonebrook Private Inc.'s holdings in DexCom were worth $572,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors also recently modified their holdings of DXCM. Norges Bank purchased a new position in shares of DexCom during the fourth quarter valued at approximately $385,367,000. Woodline Partners LP bought a new stake in DexCom in the 4th quarter worth approximately $63,338,000. Northern Trust Corp raised its stake in DexCom by 22.2% during the 4th quarter. Northern Trust Corp now owns 4,146,249 shares of the medical device company's stock valued at $322,454,000 after buying an additional 753,857 shares during the last quarter. Universal Beteiligungs und Servicegesellschaft mbH purchased a new stake in DexCom during the 4th quarter valued at $41,295,000. Finally, GAMMA Investing LLC lifted its holdings in shares of DexCom by 5,951.7% during the 1st quarter. GAMMA Investing LLC now owns 499,746 shares of the medical device company's stock valued at $34,128,000 after buying an additional 491,488 shares during the period. 97.75% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, EVP Sadie Stern sold 1,466 shares of the stock in a transaction that occurred on Thursday, June 26th. The stock was sold at an average price of $85.06, for a total value of $124,697.96. Following the transaction, the executive vice president owned 108,155 shares of the company's stock, valued at $9,199,664.30. This represents a 1.34% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Mark G. Foletta sold 2,750 shares of DexCom stock in a transaction on Monday, June 16th. The shares were sold at an average price of $83.13, for a total value of $228,607.50. Following the sale, the director directly owned 56,621 shares of the company's stock, valued at approximately $4,706,903.73. This trade represents a 4.63% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 27,190 shares of company stock worth $2,281,732. 0.32% of the stock is currently owned by corporate insiders.

DexCom Price Performance

Shares of NASDAQ:DXCM traded up $0.59 during midday trading on Thursday, reaching $85.46. 3,669,900 shares of the company were exchanged, compared to its average volume of 4,423,943. The stock has a market cap of $33.51 billion, a PE ratio of 63.78, a price-to-earnings-growth ratio of 1.81 and a beta of 1.44. The business's fifty day moving average is $84.01 and its two-hundred day moving average is $79.93. DexCom, Inc. has a one year low of $57.52 and a one year high of $117.19. The company has a current ratio of 1.50, a quick ratio of 1.32 and a debt-to-equity ratio of 0.55.

DexCom (NASDAQ:DXCM - Get Free Report) last posted its earnings results on Thursday, May 1st. The medical device company reported $0.32 EPS for the quarter, missing analysts' consensus estimates of $0.33 by ($0.01). The firm had revenue of $1.04 billion during the quarter, compared to analysts' expectations of $1.02 billion. DexCom had a return on equity of 30.05% and a net margin of 12.90%. DexCom's quarterly revenue was up 12.5% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.32 earnings per share. As a group, analysts predict that DexCom, Inc. will post 2.03 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several brokerages recently commented on DXCM. Cfra Research raised DexCom to a "hold" rating in a report on Friday, March 21st. Wall Street Zen downgraded DexCom from a "buy" rating to a "hold" rating in a research note on Sunday, June 29th. Canaccord Genuity Group increased their price objective on shares of DexCom from $103.00 to $106.00 and gave the stock a "buy" rating in a research note on Friday, May 2nd. Mizuho initiated coverage on shares of DexCom in a report on Thursday, April 10th. They issued an "outperform" rating and a $85.00 price objective on the stock. Finally, Barclays upped their target price on shares of DexCom from $90.00 to $93.00 and gave the company an "equal weight" rating in a report on Monday, May 5th. Five equities research analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and three have issued a strong buy rating to the company's stock. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $98.50.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.